Citations

Clear

1320 citation(s) found for "Nguyen, Vi".

PROGNOSTIC FACTORS AND IMPACT OF ETOPOSIDE IN ADULTS WITH SYSTEMIC ALK‐POSITIVE ANAPLASTIC LARGE‐CELL LYMPHOMA: A POOLED ANALYSIS OF SIX STUDIES
Nguyen, Dinh-Phong , Schmitz, Norbert , Lamant, Laurence , Weisenburger, Dennis D. , Ziepert, Marita , Bast, M., Tilly, H., Jaïs, Jean Philippe, Sibon, David , Suzuki, Ritsuro , Feldman, Andrew L. , Gressin, Rémy , Nakamura, Shôji , Maurer, Matthew J. , Armitage, Jamés O. , Vose, Julie M. , Savage, Kerry J.

Mayo Clinic

Hematological Oncology | June 7, 2017 | Volume: 35 | Issue: S2 | Pages: 240-240

10.1002/hon.2438_103 Get It

Secondary Somatic Mutations Restoring RAD51C and RAD51D Associated with Acquired Resistance to the PARP Inhibitor Rucaparib in High-Grade Ovarian Carcinoma
Kondrashova, Olga , Nguyen, Minh , Shield‐Artin, Kristy , Tinker, Anna V. , Teng, Nelson N.H., Harrell, Maria I., Barker, Holly E. , Prakash, Rohit , Kass, Elizabeth M. , Sullivan, Meghan R. , Brunette, Gregory J. , Bernstein, Kara A. , Floquet, Anne , Friedländer, Michael , O’Malley, David M. , Oza, Amit M. , Robillard, Liliane, Maloney, Lara , Bowtell, David D.L. , Giordano, Heidi, Wakefield, Matthew J. , Simmons, Andrew D. , Harding, Thomas C., Raponi, Mitch , McNeish, Iain A. , Swisher, Elizabeth M. , Scott, Clare L. , Lin, Kevin K. , Kaufmann, Scott H. , Kuiper, Michael J. , Ho, Gwo‐Yaw , Jasin, Maria , Sullivan, Meghan R. , Coleman, Robert L. , Kichenadasse, Ganessan , Sun, James X. , Lin, Kevin , McNeish, Iain A , Swisher, Elizabeth M , Friedlander, Michael , Wakefield, Matthew J , Scott, Clare L , Bernstein, Kara A , Kondrashova, Olga , Bowtell, David D , Barker, Holly E , O'Malley, David M

Mayo Clinic

Cancer Discovery | June 6, 2017 | Volume: 7 | Issue: 9 | Pages: 984-998

10.1158/2159-8290.cd-17-0419 | PMID 28588062 Get It

Abstract High-grade epithelial ovarian carcinomas containing mutated BRCA1 or BRCA2 (BRCA1/2) homologous recombination (HR) genes are sensitive to platinum-based chemotherapy and PARP inhibitors (PARPi), while restoration of HR function due to secondary mutations in BRCA1/2 has been recognized as an important resistance mechanism. We sequenced core HR pathway genes in 12 pairs of pretreatment and postprogression tumor biopsy samples collected from patients in ARIEL2 Part 1, a phase II study of the PARPi rucaparib as treatment for platinum-sensitive, relapsed ovarian carcinoma. In 6 of 12 pretreatment biopsies, a truncation mutation in BRCA1, RAD51C, or RAD51D was identified. In five of six paired postprogression biopsies, one or more secondary mutations restored the open reading frame. Four distinct secondary mutations and spatial heterogeneity were observed for RAD51C. In vitro complementation assays and a patient-derived xenograft, as well as predictive molecular modeling, confirmed that resistance to rucaparib was associated with secondary mutations. Significance: Analyses of primary and secondary mutations in RAD51C and RAD51D provide evidence for these primary mutations in conferring PARPi sensitivity and secondary mutations as a mechanism of acquired PARPi resistance. PARPi resistance due to secondary mutations underpins the need for early delivery of PARPi therapy and for combination strategies. Cancer Discov; 7(9); 984–98. ©2017 AACR. See related commentary by Domchek, p. 937. See related article by Quigley et al., p. 999. See related article by Goodall et al., p. 1006. This article is highlighted in the In This Issue feature, p. 920
Prevalence of Abnormal Pap Smear in Women Undergoing Liver Transplantation [15E]
Threadcraft, Marcus , Guha, Paulami, Wells, A. Judson , Dinh, Tri, Nguyen, Justin H. , Harnois, Denise M.

Mayo Clinic

Obstetrics & Gynecology | May 6, 2017 | Volume: 129 | Issue: 1 | Pages: 55S-56S

10.1097/01.aog.0000514806.16797.34 Get It

INTRODUCTION: Female patients being evaluated for liver transplantation (LT) routinely undergo a gynecologic exam including cervical cancer screening. The prevalence of cervical cytologic abnormalities in this high risk population is unknown. Our study determines prevalence of cervical cytologic abnormalities, HPV positive status, and risk factors for abnormal cervical screening for this population. METHODS: With Institutional review board approval, we reviewed 375 charts of women undergoing evaluation for LT from 2008‒2013 at Mayo Clinic Florida. We recorded demographics, Pap smear results, High risk HPV positive results, and co-morbid conditions. Univariate analysis was done to determine risk factors. We compared the result of the LT group to the general female population getting cervical cancer screening during the same time period. RESULTS: 37 of 375 (9.86%) LT patients had abnormal Pap smear, compared to 1784 of 26118 (6.83%) of the general population patients (p < 0.01). Among LT patients with cervical cytologic abnormalities, 40.5% were ASCUS, HPV positive (64.8% for non-LT patients), 29.7% were LSIL (28.1% for non-LT patients), 5.4% were HSIL (6.7% for non-LT patients) and 24.3% were cytology negative with HPV positive (0.2% for non-LT patients, p < 0.05). Younger age and presence of hypertension were associated with higher risk of having an abnormal cervical cytology or positive HPV status among LT patients. CONCLUSION: Patients undergoing evaluation for LT have increased prevalence of abnormal cervical cytology, or a positive High risk HPV test. Gynecologic surveillance for this high risk population is recommended.
Epidural Hematoma Following Cervical Spine Surgery
Schroeder, Gregory D. , Hilibrand, Alan S. , Fish, David E., Wang, Jeffrey C. , Smith, Zachary A. , Hsu, Wellington K. , Gokaslan, Ziya L. , Isaacs, Robert E., Kanter, Adam S. , Mroz, Thomas E. , Sasso, Rick C., Fehlings, Michael G. , Buser, Zorica , Bydon, Mohamad , Cha, Peter I., Chatterjee, Dhananjay, Gee, Erica L., Lord, Elizabeth L. , Mayer, Erik N. , McBride, Owen J., Nguyen, Emily C., Roe, Allison K. , Tortolani, P. Justin, Stroh, D. Alex, Yanez, Marisa Y., Arnold, Paul M. , Gum, Jeffrey L. , Nassr, Ahmad , Cha, Peter I., Riew, Kiehyun Daniel , Fehlings, Michael G

Mayo Clinic

Global Spine Journal | April 19, 2017 | Volume: 7 | Issue: 1_suppl | Pages: 120S-126S

10.1177/2192568216687754 | PMID 28451483 Get It

Study Design: A multicentered retrospective case series. Objective: To determine the incidence and circumstances surrounding the development of a symptomatic postoperative epidural hematoma in the cervical spine. Methods: Patients who underwent cervical spine surgery between January 1, 2005, and December 31, 2011, at 23 institutions were reviewed, and all patients who developed an epidural hematoma were identified. Results: A total of 16 582 cervical spine surgeries were identified, and 15 patients developed a postoperative epidural hematoma, for a total incidence of 0.090%. Substantial variation between institutions was noted, with 11 sites reporting no epidural hematomas, and 1 site reporting an incidence of 0.76%. All patients initially presented with a neurologic deficit. Nine patients had complete resolution of the neurologic deficit after hematoma evacuation; however 2 of the 3 patients (66%) who had a delay in the diagnosis of the epidural hematoma had residual neurologic deficits compared to only 4 of the 12 patients (33%) who had no delay in the diagnosis or treatment ( P = .53). Additionally, the patients who experienced a postoperative epidural hematoma did not experience any significant improvement in health-related quality-of-life metrics as a result of the index procedure at final follow-up evaluation. Conclusion: This is the largest series to date to analyze the incidence of an epidural hematoma following cervical spine surgery, and this study suggest that an epidural hematoma occurs in approximately 1 out of 1000 cervical spine surgeries. Prompt diagnosis and treatment may improve the chance of making a complete neurologic recovery, but patients who develop this complication do not show improvements in the health-related quality-of-life measurements.
Identifying a subset of patients with DCIS who have a low likelihood of residual disease at surgical excision following a core needle biopsy
Murphy, Brittany L. , Gonzalez, Alexandra B., Conners, Amy Lynn , Henrichsen, Tara L. , Keeney, Michael, Chen, Beiyun, Nguyen, Toan T. , Harmsen, William S. , Habermann, Elizabeth B. , Shah, Harsh N. , Jakub, James W. , Conners, Amy L, Keeney, Michael G., Jakub, James W , Habermann, Elizabeth

Mayo Clinic

Journal of Surgical Oncology | April 18, 2017 | Volume: 116 | Issue: 2 | Pages: 213-219

10.1002/jso.24649 | PMID 28420032 Get It

Background and ObjectivesCurrent randomized controlled trials are investigating the outcomes of non‐surgical treatment for patients with ductal carcinoma in situ (DCIS). We sought to evaluate pre‐operative factors associated with no residual disease at definitive resection following a core needle biopsy (CNB) diagnosis of DCIS.MethodsEight hundred and thirty‐four operations for DCIS were performed at our institution between January 2004 and October 2014. We evaluated patient and biopsy tumor characteristics to determine pre‐operative factors associated with no residual disease at surgical resection using uni‐ and multivariable analyses.ResultsSixty‐nine patients (8%) had no residual disease on final pathology. On multivariable analysis, low‐ or intermediate‐grade lesions, <1 cm in size on mammography, and lesions where ≥90% of calcifications were removed correlated with finding no residual disease on final pathology, c‐statistic 0.84. Of the 14 patients with all three low‐risk factors, 36% had no residual disease on final pathology.ConclusionsAlthough our multivariable analysis performed well, its clinical utility would be limited as we were unable to identify a subset of patients with DCIS in whom the probability of finding no residual disease is low enough to consider routine use of non‐surgical management.
Luminal and basal subtyping of prostate cancer.
Feng, Felix Y. , Zhao, Shuang G. , Erho, Nicholas , Lehrer, Jonathan , Alshalalfa, Mohammed , Ryan, Charles J. , Freedland, Stephen J. , Posadas, Edwin M. , Ross, Ashley E. , Karnes, Jeffrey , Zhao, Shuang G , Chang, S. Laura , Cooperberg, Matthew R , Kim, Won Bae , Den, Robert B. , Klein, Eric A. , Davicioni, Elai , Schaeffer, Edward M. , Nguyen, Paul L. , Carroll, Peter R , Spratt, Daniel E.

Mayo Clinic

Journal of Clinical Oncology | March 29, 2017 | Volume: 35 | Issue: 6_suppl | Pages: 3-3

10.1200/jco.2017.35.6_suppl.3 Get It

3 Background: There is a clear need to develop a clinically relevant molecular subtyping approach for prostate cancer. We hypothesized that prostate cancer can be subtyped based on luminal versus basal lineage. Methods: We applied the PAM50 classifier, which is used clinically to identify luminal and basal cancers in breast cancer, to subtype a total of 3,782 prostate cancer samples using a high-density microarray platform run in a CLIA-certified laboratory. We examined the associations of these subtypes and clinical outcomes. Results: We demonstrate that PAM50 segregates prostate cancer into three reproducible subtypes in both retrospective cohorts and on prospective validation: luminal A (33.3%-34.3%), luminal B (28.5%-32.6%), and basal (34.1%-37.1%). Luminal B prostate cancers exhibited the worst clinical prognoses, followed by basal and luminal A subtypes (10-year biochemical recurrence-free survival: 29/39/41%; distant metastasis-free survival: 53/73/73%; prostate cancer-specific survival: 78/86/89%; overall survival: 69/80/82% respectively) on both univariable and multivariable analyses accounting for standard clinicopathologic prognostic factors. Known luminal lineage markers, such as NKX3.1 and KRT18, and the basal lineage CD49f signature, were enriched in luminal- and basal-like cancers respectively, demonstrating the connection between these subtypes and established prostate cancer biology. While both luminal-like subtypes were associated with increased AR expression and signaling, only luminal B prostate cancers were significantly associated with post-operative response to androgen deprivation therapy (ADT) in a subset analysis matching patients based on clinicopathologic variables (interaction p = 0.006, luminal B 10-year metastasis: 33% (treated) vs. 55% (untreated), non-luminal B: 37% (treated) vs. 21% (untreated)). Conclusions: These findings contribute novel insight into the biology of prostate cancer, and provide translatable clinical tools for personalizing post-operative ADT for patients with prostate cancer. Similar to breast cancer, these findings suggest that luminal/basal subtyping may be useful in treatment selection in prostate cancer.
Maintenance of the HIV Reservoir Is Antagonized by Selective BCL2 Inhibition
Sainski‐Nguyen, Amy , Natesampillai, Sekar, Aboulnasr, Fatma, Badley, Andrew D. , Cummins, Nathan W. , Sainski-Nguyen, Amy M, Kaufmann, Scott, Kaufmann, Scott H. , Badley, Andrew D

Mayo Clinic

Journal of Virology | March 23, 2017 | Volume: 91 | Issue: 11 | Pages: No page available

10.1128/jvi.00012-17 | PMID 28331083 Get It

ABSTRACTDecay of the HIV reservoir is slowed over time in part by expansion of the pool of HIV-infected cells. This expansion reflects homeostatic proliferation of infected cells by interleukin-7 (IL-7) or antigenic stimulation, as well as new rounds of infection of susceptible target cells. As novel therapies are being developed to accelerate the decay of the latent HIV reservoir, it will be important to identify interventions that prevent expansion and/or repopulation of the latent HIV reservoir. Our previous studies showed that HIV protease cleaves the host protein procaspase 8 to generate Casp8p41, which can bind and activate Bak to induce apoptosis of infected cells. In circumstances where expression of the anti-apoptotic protein BCL2 is high, Casp8p41 instead binds BCL2, and cell death does not occur. This effect can be overcome by treating cells with the clinically approved BCL2 antagonist venetoclax, which prevents Casp8p41 from binding BCL2, thereby allowing Casp8p41 to bind Bak and kill the infected cell. Here we assess whether the events that maintain the HIV reservoir are also antagonized by venetoclax. Using the J-Lat 10.6 model of persistent infection, we demonstrate that proliferation and HIV expression are countered by the use of venetoclax, which causes preferential killing of the HIV-expressing cells. Similarly, during new rounds of infection of primary CD4 T cells, venetoclax causes selective killing of HIV-infected cells, resulting in decreased numbers of HIV DNA-containing cells.IMPORTANCECure of HIV infection requires an intervention that reduces the HIV reservoir size. A variety of approaches are being tested for their ability to impact HIV reservoir size. Even if successful, however, these approaches will need to be combined with additional complementary approaches that prevent replenishment or repopulation of the HIV reservoir. Our previous studies have shown that the FDA-approved BCL2 antagonist venetoclax has a beneficial effect on the HIV reservoir size following HIV reactivation. Here we demonstrate that venetoclax also has a beneficial effect on HIV reservoir size in a model of homeostatic proliferation of HIV as well as in acute spreading infection of HIV in primary CD4 T cells. These results suggest that venetoclax, either alone or in combination with other approaches to reducing HIV reservoir size, is a compound worthy of further study for its effects on HIV reservoir size.